TRVI - CIK 0001563880
Trevi Therapeutics, Inc. (TRVI) reported net income of -$42.76M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$42.76M | +10.7% |
| FY 2024 | -$47.91M | -64.8% |
| FY 2023 | -$29.07M | +0.3% |
| FY 2022 | -$29.15M | +14.1% |
| FY 2021 | -$33.94M | -3.6% |
| FY 2020 | -$32.76M | -25.8% |
| FY 2019 | -$26.05M | -26.8% |
| FY 2018 | -$20.55M | - |
Trevi Therapeutics, Inc. (TRVI) reported net income of -$42.76M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Trevi Therapeutics, Inc.'s net income declined from -$20.55M to -$42.76M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.